NASDAQ:AMRS - Amyris Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $2.26 -0.52 (-18.71 %) (As of 03/24/2019 04:00 PM ET)Previous Close$2.26Today's Range$2.17 - $2.8052-Week Range$2.17 - $9.28Volume6.22 million shsAverage Volume2.11 million shsMarket Capitalization$172.96 millionP/E Ratio-0.89Dividend YieldN/ABeta0.39 ProfileDiscussionAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Amyris, Inc., an integrated renewable products company, delivers alternatives to petroleum, plant, and animal-based products across a range of consumer and industry segments worldwide. It applies its bioscience solutions to convert plant sugars into hydrocarbon molecules, specialty ingredients, and consumer products. The company delivers its No Compromise products and services in markets, such as specialty and performance chemicals, flavors and fragrances, cosmetics ingredients, pharmaceuticals, and nutraceuticals. The company was formerly known as Amyris Biotechnologies, Inc. and changed its name to Amyris, Inc. in June 2010. Amyris, Inc. was founded in 2003 and is headquartered in Emeryville, California. Receive AMRS News and Ratings via Email Sign-up to receive the latest news and ratings for AMRS and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Industrial organic chemicals Sub-IndustryOil & Gas Refining & Marketing SectorBasic Materials Current SymbolNASDAQ:AMRS Previous Symbol CUSIP03236M10 CIK1365916 Webwww.amyris.com Phone510-450-0761Debt Debt-to-Equity RatioN/A Current Ratio0.44 Quick Ratio0.40Price-To-Earnings Trailing P/E Ratio-0.89 Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$80.42 million Price / Sales2.15 Cash FlowN/A Price / Cash FlowN/A Book Value($4.64) per share Price / Book-0.49Profitability EPS (Most Recent Fiscal Year)($2.53) Net Income$-72,320,000.00 Net Margins-255.65% Return on EquityN/A Return on Assets-180.12%Miscellaneous Employees414 Outstanding Shares76,530,000Market Cap$172.96 million Next Earnings Date5/13/2019 (Estimated) OptionableOptionable Amyris (NASDAQ:AMRS) Frequently Asked Questions What is Amyris' stock symbol? Amyris trades on the NASDAQ under the ticker symbol "AMRS." When did Amyris' stock split? How did Amyris' stock split work? Amyris shares reverse split before market open on Tuesday, June 6th 2017. The 1-15 reverse split was announced on Tuesday, June 6th 2017. The number of shares owned by shareholders was adjusted after the closing bell on Monday, June 5th 2017. An investor that had 100 shares of Amyris stock prior to the reverse split would have 7 shares after the split. How were Amyris' earnings last quarter? Amyris Inc (NASDAQ:AMRS) posted its quarterly earnings data on Monday, March, 18th. The biotechnology company reported ($1.07) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of $0.44 by $1.51. The biotechnology company earned $19.36 million during the quarter, compared to analyst estimates of $98.52 million. The business's revenue was down 76.0% on a year-over-year basis. During the same period in the previous year, the firm posted $0.61 EPS. View Amyris' Earnings History. When is Amyris' next earnings date? Amyris is scheduled to release their next quarterly earnings announcement on Monday, May 13th 2019. View Earnings Estimates for Amyris. What price target have analysts set for AMRS? 2 analysts have issued 1-year target prices for Amyris' stock. Their forecasts range from $8.00 to $11.00. On average, they expect Amyris' stock price to reach $9.50 in the next twelve months. This suggests a possible upside of 320.4% from the stock's current price. View Analyst Price Targets for Amyris. What is the consensus analysts' recommendation for Amyris? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Amyris in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Amyris. What are Wall Street analysts saying about Amyris stock? Here are some recent quotes from research analysts about Amyris stock: 1. According to Zacks Investment Research, "Amyris INC is an integrated renewable products company applying industrial synthetic biology to genetically modify microorganisms to serve as living factories. Amyris designs these microorganisms to produce defined molecules for use as renewable chemicals and transportation fuels. The Company is engaged in the development of farmesene- a molecule, which serves as the base chemical building block for a wide range of renewable products to replace existing products that are derived from petroleum, plant or animal sources and that may be of lower quality or higher price. Amyris INC is headquartered in Emeryville, CA. " (1/15/2019) 2. HC Wainwright analysts commented, "We believe the company is capitalizing on its relationship with Xinfu / Yifan to monetize a portion of the long-term royalty opportunity upfront, which should lower quarterly volatility from this high-margin revenue stream while continuing to benefit from future royalty payments." (12/31/2018) Has Amyris been receiving favorable news coverage? Headlines about AMRS stock have been trending neutral this week, according to InfoTrie Sentiment Analysis. The research group scores the sentiment of news coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Amyris earned a daily sentiment score of 0.2 on InfoTrie's scale. They also assigned press coverage about the biotechnology company a news buzz of 3.0 out of 10, meaning that recent news coverage is unlikely to have an impact on the stock's share price in the next several days. Are investors shorting Amyris? Amyris saw a increase in short interest during the month of February. As of February 15th, there was short interest totalling 12,270,628 shares, an increase of 29.1% from the January 31st total of 9,507,136 shares. Based on an average daily volume of 9,309,778 shares, the short-interest ratio is currently 1.3 days. Approximately 32.0% of the shares of the company are sold short. View Amyris' Current Options Chain. Who are some of Amyris' key competitors? Some companies that are related to Amyris include FutureFuel (FF), REX American Resources (REX), Green Plains Partners (GPP), Sino United Worldwide Consolidated (SUIC), Solarwindow Technologies (WNDW), CTD (CTDH), Pacific Ethanol (PEIX), Tantech (TANH), Wave Sync (WAYS), Gevo (GEVO), Aemetis (AMTX), OriginClear (OCLN), Methes Energies International (MEIL) and Mission Newenergy (MNELF). What other stocks do shareholders of Amyris own? Based on aggregate information from My MarketBeat watchlists, some companies that other Amyris investors own include Gevo (GEVO), Novavax (NVAX), Synergy Pharmaceuticals (SGYP), Keryx Biopharmaceuticals (KERX), AVEO Pharmaceuticals (AVEO), BioDelivery Sciences International (BDSI), Exelixis (EXEL), Advanced Micro Devices (AMD), Progenics Pharmaceuticals (PGNX) and Ribbon Communications (RBBN). Who are Amyris' key executives? Amyris' management team includes the folowing people: Mr. John G. Melo, Pres, CEO & Director (Age 53)Ms. Kathleen Valiasek, Chief Financial Officer (Age 55)Mr. Eduardo Alvarez, Chief Operating Officer (Age 55)Ms. Nicole Kelsey, Gen. Counsel & Sec. (Age 52)Dr. Joel R. Cherry, Pres of R&D (Age 58) Who are Amyris' major shareholders? Amyris' stock is owned by many different of institutional and retail investors. Top institutional investors include BlackRock Inc. (4.47%), Northpointe Capital LLC (0.83%), WS Management Lllp (0.82%), Geode Capital Management LLC (0.53%), Geode Capital Management LLC (0.53%) and Northern Trust Corp (0.51%). Company insiders that own Amyris stock include (Mauritius) Pte Ltd Maxwell, Eduardo Alvarez, Frank Kung, John Melo, Kathleen Valiasek, L John Doerr and Patrick Y Yang. View Institutional Ownership Trends for Amyris. Which major investors are selling Amyris stock? AMRS stock was sold by a variety of institutional investors in the last quarter, including Two Sigma Investments LP, B. Riley Financial Inc. and KBC Group NV. Company insiders that have sold Amyris company stock in the last year include (Mauritius) Pte Ltd Maxwell, Frank Kung, John Melo and L John Doerr. View Insider Buying and Selling for Amyris. Which major investors are buying Amyris stock? AMRS stock was purchased by a variety of institutional investors in the last quarter, including BlackRock Inc., WS Management Lllp, Pinnacle Associates Ltd., Northpointe Capital LLC, Barclays PLC, Virtus ETF Advisers LLC, Bank of America Corp DE and Principal Financial Group Inc.. Company insiders that have bought Amyris stock in the last two years include Eduardo Alvarez, Kathleen Valiasek and Patrick Y Yang. View Insider Buying and Selling for Amyris. How do I buy shares of Amyris? Shares of AMRS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Amyris' stock price today? One share of AMRS stock can currently be purchased for approximately $2.26. How big of a company is Amyris? Amyris has a market capitalization of $172.96 million and generates $80.42 million in revenue each year. The biotechnology company earns $-72,320,000.00 in net income (profit) each year or ($2.53) on an earnings per share basis. Amyris employs 414 workers across the globe. What is Amyris' official website? The official website for Amyris is http://www.amyris.com. How can I contact Amyris? Amyris' mailing address is 5885 HOLLIS STREET SUITE 100, EMERYVILLE CA, 94608. The biotechnology company can be reached via phone at 510-450-0761 or via email at [email protected] MarketBeat Community Rating for Amyris (NASDAQ AMRS)Community Ranking: 2.1 out of 5 ( )Outperform Votes: 247 (Vote Outperform)Underperform Votes: 328 (Vote Underperform)Total Votes: 575MarketBeat's community ratings are surveys of what our community members think about Amyris and other stocks. Vote "Outperform" if you believe AMRS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AMRS will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 3/24/2019 by MarketBeat.com StaffFeatured Article: How much can an individual set aside as a catch-up contribution?